Posted on August 25, 2012 by Sitemaster
It is rapidly becoming apparent that we are going to need two simple, new terms to be able to use in discussion of the evolution of progressive prostate cancer after “standard” forms of androgen deprivation therapy (ADT) have failed to work. So … anyone got good, scientifically sound suggestions? … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, androgen-independent, castration-resistant, hormone refractory, terminology | 7 Comments »
Posted on July 7, 2011 by Sitemaster
According to a media release from Regeneron Pharmaceuticals, the company plans to continue the randomized, multi-center, Phase III VENICE clinical trial, designed to evaluate the efficacy and safety of aflibercept (ZALTRAP™) in combination with docetaxel in the first-line treatment of patients with metastatic, hormone-refractory prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: aflibercept, hormone refractory, Regeneron, trial | 8 Comments »
Posted on June 12, 2010 by Sitemaster
Back in 2008 we first mentioned the initiation of clinical trials of a drug called Apoptone or HE3235 in men with hormone-refractory prostate cancer. Data on the development of Apoptone was another item on the agenda at the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this week. … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: Apoptone, castration-resistant, HE3235, hormone refractory | Leave a comment »
Posted on June 8, 2010 by Sitemaster
At major medical meetings like the recent AUA and ASCO annual meetings (the latter wrapping up today in Chicago), what goes on in the conversations in the corridors and in private meetings is often more important and interesting than what is being presented from the podium or talked about at poster sessions. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, hormone refractory | 15 Comments »
Posted on April 22, 2010 by Sitemaster
Beyond abiraterone acetate and MDV3100 and even TAK-700, a new generation of treatments for hormonally driven cancers like prostate cancer (and breast cancer) is being explored by start-up companies like Aragon Pharmaceuticals. … READ MORE …
Filed under: Drugs in development | Tagged: Aragon Pharmaceuticals, castration-resistant, hormone refractory, selective androgen receptor degrader | 1 Comment »
Posted on August 2, 2009 by Sitemaster
Only two news reports of any significance this weekend, on:
- Pesticides and prostate cancer risk in Martinique
- The transition from hormone-sensitive to hormone-refractory disease … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment, Uncategorized | Tagged: castration-resistant, hormone refractory, hormone-sensitive, incidence, Martinique, pesticides, risk | Leave a comment »
Posted on July 31, 2008 by Sitemaster
News items today are focused on information about:
- a new way of approaching treatment of hormone-refractory disease
- the initial clinical trials of a new drug candidate in hormone-refractory patients
- the association between hospital and surgeon volume and patient outcomes after radical prostatectomy. … MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Apoptone, cancer, HE3235, hormone refractory, hospital, news, prostate, prostatectomy, radical, update, volume | Leave a comment »
Posted on July 29, 2008 by Sitemaster
Here is Part B of your daily prostate cancer news update. Unless someone announces a cure for prostate cancer we will probably hold any further news until tomorrow! … MORE …
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: AIPC, androgen-independent, cancer, cut-point, hormone refractory, HRPC, laparoscopic, margin, news, open, positive, prostate, prostatectomy, PSA, PSM, radical, somastatin, surgical, update | 1 Comment »
Posted on July 28, 2008 by Sitemaster
In today’s prostate cancer news:
- More on the effects of hormone therapy on cognitive function and
- The application to market satraplatin has been withdraw in Europe … MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cancer, cognitive function, hormone, hormone refractory, prostate, satraplatin, therapy | Leave a comment »
Posted on July 23, 2008 by Sitemaster
For some reason, the major media have decided that abiraterone acetate is “a wonder drug” that is going to solve all of the problems of men with hormone refractory prostate cancer and maybe more. The following is a quotation from a story in today’s Los Angeles Times: … MORE …
Filed under: Drugs in development, Treatment | Tagged: abiraterone, cancer, hormone refractory, prostate | 17 Comments »
